Australia's Tissue Repair eyes best day ever on FDA phase 3 approval
** Shares of biopharmaceutical co Tissue Repair Ltd TRP.AX
rise as much as 20% to A$0.30, on track for their best day ever,
if gains hold
** TRP says U.S. Food and Drug Administration (FDA)
provided clearance for the co to progress into a Phase 3 program
for drug candidate TR-987
** Co says it will now submit its Phase 3 protocol for final
review by FDA and clearance for patient enrolment
** TRP stock at its highest level since Jan 18
** Stock up 8.7% YTD, as of last close
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Recent news on Tissue Repair
See all newsBrief: Tissue Repair Resumes Direct Distribution Of TR Pro+ In Australia, New Zealand
Brief: Tissue Repair Posts FY Loss Attributable Of A$5.4 Million
Brief: Tissue Repair Says Formally Applied To ASX Requesting Its Removal From Official List Of ASX
Brief: Tissue Repair Signs A Multi-Year Distribution Agreement With Advanced Cosmeceuticals Pty
Australia's Tissue Repair rises to 3-month high on securing distributor for flagship product